Dr. David Reardon on Immunotherapy and Rindopepimut in the Glioblastoma Treatment Paradigm

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm. Reardon says rindopepimut is the first immunotherapy to ever show a survival benefit in glioblastoma and hopes a randomized phase III double blind trial with a placebo control arm will allow the drug to make bigger strides in the treatment of the malignancy.